leisure time -WSS

leisure time

author：explore 2025-10-01 20:16:25 - browse：15

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Hilary expected to bring catastrophic, life

explore

WSS

Majority of Americans think Trump's Ga. election interference case is serious: POLL

As Maui death toll rises, number of missing remains unclear

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Living with Hashimoto's and celiac disease, and med school, too

Clinical trials must include more disabled people

Senate HELP committee spars over health care workforce policies

leisure time

leisure time

entertainment

Activists slam private health insurers over coverage restrictions

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Moonlake's readout produced a cash windfall. Risks remain

ProMED sees offers of support, but its future remains unclear

Psychedelics group wrestles with new pharma identity

ActiGraph execs on goal of drug approvals with digital endpoints

After affirmative action ruling, medical educators look to 'holistic review'

Hilary may become 1st tropical storm to make landfall in California in 84 years

Affirmative action in medical school literally saved lives

ProMED sees offers of support, but its future remains unclear

leisure time

How AI helped researchers track recovery from depression

Hearing on Medicare drug price negotiation gets unusually heated

CommonSpirit Health keeps growing, even as it loses money

Cancer drug shortages' outsize impact on ovarian cancer patients

Intarcia’s device

Congress must give Medicare recipients genetic counseling access

knowledge

explore

entertainment

hotspot